EUVIMEDOpdag EUVIMED
FallberichtOpen access · CC BY-NC-ND 4.0

Pediatric Primary Cutaneous CD8 + Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course

Carrie Meng iD, Auris Huen, David McCall, Phyu P Aung, Priyadharsini Nagarajan, Valentina Nardi iD, Carlos A Torres-Cabala iD

Journal of Cutaneous Pathology · 2025

DOI: 10.1111/cup.70037 ↗

At a glance

Fallbericht in Journal of Cutaneous Pathology, 2025. Written by Carrie Meng and 6 co-authors. Institution: Baylor College of Medicine, Houston, Texas, USA. Major MEDLINE topics: Lymphoma, T-Cell, Cutaneous, Skin Neoplasms, T-Lymphocytes, Cytotoxic, CD8-Positive T-Lymphocytes. 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T‐cell lymphoma (PCAECTCL) is a rare and aggressive malignancy, with limited documented cases in pediatric patients. This report presents a unique case of a 9‐year‐old female with PCAECTCL, characterized by widespread erythematous annular lesions that exhibited an indolent clinical course that lasted four years after the development of the initial lesion, contrasting with the typically rapid progression seen in adults. Histopathological and immunohistochemical analyses revealed an atypical CD8+ T‐cell infiltrate with marked epidermotropism, loss of CD2 and CD5 expression, and positivity for cytotoxic markers TIA‐1 and granzyme B. Molecular studies identified a PCM1::JAK2 gene fusion, linking the disease to JAK/STAT pathway dysregulation, which is a finding previously unreported in pediatric PCAECTCL. Despite partial responses to topical therapies, oral prednisone, and methotrexate, the disease persisted, highlighting therapeutic challenges. This case underscores the importance of molecular profiling in PCAECTCL and suggests potential utility for JAK inhibitors like ruxolitinib.

Subjects

MeSH terms (MEDLINE)

Lymphoma, T-Cell, CutaneousSkin NeoplasmsT-Lymphocytes, CytotoxicCD8-Positive T-LymphocytesHumansFemaleChildJanus Kinase 2

Author keywords

Berti lymphomaCD8+ T‐cell lymphomaJAK2PCM1epidermotropicpediatric

Substances

Janus Kinase 2JAK2 protein, human

Authors and institutions

  • Baylor College of Medicine, Houston, Texas, USA.
  • University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.

ORCID profiles: Carrie Meng, Valentina Nardi, Carlos A Torres-Cabala

Cite

APA

Meng, C., Huen, A., McCall, D., Aung, P. P., Nagarajan, P., Nardi, V., & Torres-Cabala, C. A. (2025). Pediatric Primary Cutaneous CD8 + Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.70037

Vancouver

Meng C, Huen A, McCall D, Aung PP, Nagarajan P, Nardi V, et al. Pediatric Primary Cutaneous CD8 + Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course. Journal of Cutaneous Pathology. 2025. doi:10.1111/cup.70037

BibTeX
@article{Meng2025,
  author = {Meng, Carrie and Huen, Auris and McCall, David and Aung, Phyu P and Nagarajan, Priyadharsini and Nardi, Valentina and Torres-Cabala, Carlos A},
  title = {Pediatric Primary Cutaneous CD8 + Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course},
  journal = {Journal of Cutaneous Pathology},
  year = {2025},
  doi = {10.1111/cup.70037}
}
Start for free →